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Background: Changes in respiratory tract microbiota have been associated with diseases such as tuberculosis, a
global public health problem that affects millions of people each year. This pilot study was carried out using
sputum, oropharynx, and nasal respiratory tract samples collected from patients with pulmonary tuberculosis and
healthy control individuals, in order to compare sample types and their usefulness in assessing changes in bacterial
and fungal communities.
Findings: Most V1-V2 16S rRNA gene sequences belonged to the phyla Firmicutes, Bacteroidetes, Proteobacteria,
Actinobacteria, and Fusobacteria, with differences in relative abundances and in specific taxa associated with each
sample type. Most fungal ITS1 sequences were classified as Ascomycota and Basidiomycota, but abundances
differed for the different samples. Bacterial and fungal community structures in oropharynx and sputum samples
were similar to one another, as indicated by several beta diversity analyses, and both differed from nasal samples.
The only difference between patient and control microbiota was found in oropharynx samples for both bacteria
and fungi. Bacterial diversity was greater in sputum samples, while fungal diversity was greater in nasal samples.
Conclusions: Respiratory tract microbial communities were similar in terms of the major phyla identified, yet they
varied in terms of relative abundances and diversity indexes. Oropharynx communities varied with respect to health
status and resembled those in sputum samples, which are collected from tuberculosis patients only due to the
difficulty in obtaining sputum from healthy individuals, suggesting that oropharynx samples can be used to analyze
community structure alterations associated with tuberculosis.
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tuberculosisFindings
Recent studies suggest that microbial communities inha-
biting the human body can influence the host's health
status and contribute to disease [1]. The human upper
respiratory tract represents the major portal of entry for
numerous airborne microorganisms, such as bacteria,
fungi, or viruses [2]. High-throughput sequencing me-
thods have provided great insight regarding the com-
position of the respiratory tract-associated microbiota,* Correspondence: mzambrano@corpogen.org
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unless otherwise stated.which has been recently related with the development of
diseases such as asthma [3], nosocomial pneumonia,
pulmonary cystic fibrosis [4], and chronic obstructive
pulmonary disease [5].
Tuberculosis (TB), a respiratory disease caused by
Mycobacterium tuberculosis (Mtb), is a major global
public health problem that affects millions of people
each year and ranks as the second leading cause of death
from an infectious disease worldwide, with 8.6 million
new cases and 1.3 million deaths in 2012 (25% of them
were HIV-associated) [6]. The Mtb pathogen typically
affects the lungs (pulmonary TB) but can affect other
sites as well (extrapulmonary TB). Individuals withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Population characteristics
TB patients Controls
Number 6 6
Age; median (range) in years 38 (30–46) 37 (26–47)
Gender: male/female 5/1 5/1
Body mass index (BMI; kg/m2)
median (max/min)*
19.1 (21.2–16.4) 25.5 (27.6–22.5)
*p < 0.05 (obtained with U Mann-Whitney). Significant difference between TB
patients and healthy individuals.
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http://www.microbiomejournal.com/content/2/1/29pulmonary TB can expel bacteria by talking, coughing,
or sneezing, spreading the pathogen through airborne
particles that are inhaled by others. The complex Mtb-
human host interaction and the resulting infectious
process indicate that TB disease development may be a
multifactorial process [7]. Microorganism characteristics
coupled to local host immune response determine
whether bacilli are cleared or will lead to either acute or
latent disease [2].
Recent studies of the respiratory tract microbiota using
sputum samples and mixtures of saliva and pharyngeal se-
cretions indicate changes and possible associations with
pulmonary TB [8,9]. In this work, we examined the micro-
biota in three types of respiratory tract samples, nasal and
oropharynx swabs and sputum, the latter taken only from
patients since sputum is difficult to procure from healthy
individuals, not to mention the more invasive bronchoal-
veolar lavage. Previous studies have shown that oropha-
ryngeal swabs can be a reasonable proxy for lung samples
[10], and an analysis in healthy individuals indicated that
lung and upper airway bacterial populations, which in-
clude the oropharynx, were largely indistinguishable from
one another [11]. Given that the resemblance between
oropharyngeal and sputum communities is still unclear
and the difficulty of getting sputum samples from healthy
individuals, the aim of this work was to use different
sample types and determine which one could be used to
evaluate the composition of the respiratory tract micro-
biota associated with TB patients and healthy controls.
Population and sampling
To assess respiratory tract microbiota associated with TB
patients and healthy controls, we collected nasal, oropha-
rynx, and sputum samples from six TB patients and nasal
and oropharynx samples from six healthy controls. The
inclusion and exclusion criteria can be found in Additional
file 1, and the demographic and clinical characteristics of
individuals are shown in Additional file 2. Nasal samples
were taken by swabbing the mucosal surface of the deep
nasal cavity by doing ten rotational movements in each
nostril; oropharynx swabs were taken from the back wall
of the oropharynx, avoiding contact with other surfaces
such as tonsil, palate, and tongue. As previously reported,
the median body mass index (BMI) was significantly lower
in TB patients (19.6) compared to healthy controls (25.5)
(Table 1) [12]. All sputum, nasal and oropharynx samples
were collected, processed as reported [13], and used to
isolate DNA with the MoBio PowerSoil DNA Isolation Kit
(MO Bio Laboratories, Carlsbad, CA, USA) [14,15], fol-
lowing the manufacturer's recommendations.
Bacterial diversity
The V1-V2 hypervariable region of the bacterial 16S
rDNA was amplified with primers 27F (5′ AGAGTTTGATCCTGGCTCAG 3′) and 338R (5′ TGCTGCC
TCCCGTAGGAGT 3′) [16], using 10 ng DNA and Accu-
Prime™ Taq DNA polymerase (Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA) with the following con-
ditions: 95°C for 3 min, followed by 35 cycles of 20 s at
95°C, 20 s at 52°C and 60 s at 65°C, and ending with 6
min at 72°C. Samples were sequenced using 454/Roche
GS-FLX Titanium chemistry (EnGenCore, University of
South Carolina, Columbia, SC, USA). Pyrosequencing
reads have been submitted to the NCBI Sequence Read
Archive (BioProject no. PRJNA242354). All sequence
analyses were carried out using Quantitative Insights Into
Microbial Ecology (QIIME) v1.6 [17]. Approximately
589,000 sequences with a length size larger than 200 bps
remained after quality filtering (386,645 and 202,422 reads
from TB patient and control samples, respectively) using a
quality score of 25 with a slide window of 40 bases. The
open-reference operational taxonomic unit (OTU) picking
protocol was used to discard sequences that were likely
not rRNA and chimeras using 97% sequence identity and
the Greengenes core set [18]. Samples were rarified to the
minimum number of sequence reads per sample (the
number varied from 10,480 to 38,099), and taxonomic
classification was performed using the Ribosomal Data-
base Project naïve Bayesian classifier [19]. Chao1 and
Shannon indexes were calculated for taxon richness
and diversity estimations, respectively. Significance tests
were performed using the non-parametric Mann-Whitney
U test (SPSS V.18, SPSS Inc, Chicago, IL, USA). A first
comparison showed that sputum samples had the highest
diversity, followed by oropharynx and the least diverse
were nasal samples. Both nasal and oropharynx samples
from healthy controls were more diverse than samples
from TB patients, with a significant difference in the
Shannon index for nasal samples (Table 2). Most se-
quences in all samples (>99% in TB patients and >98%
in healthy controls) belonged to five phyla, Firmicutes,
Bacteroidetes, Proteobacteria, Actinobacteria, and Fuso-
bacteria, consistent with previous reports [9,20,21] (see
Figure 1A). White's non-parametric t test (pairwise com-
parisons) [22], ANOVA (multiple comparisons), and false
discovery rate (FDR) correction, all implemented in the
STAMP software [23], were used to identify groups that
could be characteristic of each sample type. STAMP
Table 2 Sequence data and diversity indexes
Sample type Characteristics Sequence type
Bacterial (16S) Fungal (ITS1)
TB Controls TB Controls
Nasal Total sequencesa 124,977 106,729 76,480 73,858 (4)
Observed OTUs 318 348 378 345
Chao1 708 627 684 585
Shannon (H') 3.0* 4.2* 6.9 6.6
Oropharynx Total sequencesa 140,987 95,693 29,759 22,376 (3)
Observed OTUs 577 882 98 131
Chao1 1262 1941 153 209
Shannon (H') 4.8 5.8 3.8 4.8
Sputum Total sequences 120,681 ND 66,278 ND
Observed OTUs 827 ND 102 ND
Chao1 1857 ND 154 ND
Shannon (H') 6.1 ND 3.4 ND
ND not available. aNumber in parenthesis indicates samples for which
sequences were obtained, if less than 6. *p < 0.05 (U Mann-Whitney) indicates
significance between TB patients and healthy controls for 16S rRNA
gene sequences.
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teroidetes (p = 0.017) and Thermi (p = 0.020) were signifi-
cantly different among sample types (nasal, oropharynx,
and sputum). Principal coordinate analyses (PCoA) and
unweighted pair group method with arithmetic mean
(UPGMA) analyses performed to compare communi-
ties indicated that oropharynx and sputum microbialFigure 1 Analysis of bacterial 16S rRNA gene sequences. (A) Taxonom
UniFrac metric (top) for sequences obtained from TB patient (P) or healthy
individuals are indicated by numbers. (B) PCoA UniFrac weighted analysis o
controls (squares) and patients (circles).communities clustered together, whereas nasal samples
clustered separately, consistent with previous analyses
of oropharynx and nasal communities [14,20] (Figure 1).
Between-group versus within-group UniFrac distances,
with permutation, were analyzed using Student's t test for
significant differences of averages to see if communities
from the same sample type were more similar to one
another than to the other communities. The oropharynx
sample communities were as similar to the sputum sample
communities as they were to each other (p > 0.05, data not
shown), and likewise, communities from sputum samples
were also indistinguishable from oropharynx communities,
indicating that they are closely related.
These differences were marked by a higher abundance
of some phyla, particularly Bacteroidetes and Fusobacteria
in oropharynx samples and Thermi in nasal swabs
(p values = 0.034, 0.030, and 0.031, respectively). Fourteen
taxa differed significantly between nasal and oropharynx
samples when both patient and control groups were ana-
lyzed together, but only some of these showed differences
within each group: one for patients versus three phyla for
controls (Table 3). When comparing sputum and oro-
pharynx communities, only for TB patients for which both
samples were collected, the only observed difference
was in Actinobacteria, which was significantly higher in
sputum samples (Figure 1A, Table 3); no significant dif-
ferences were found at other phylogenetic levels. As ex-
pected, sequences belonging to the genus Mycobacterium
were detected only in sputum but not in patient oropha-
rynx samples, consistent with culture results.ic classification (bottom) and UPGMA analysis based on unweighted
control (C) sputum (S), oropharynx (O), and nasal (N) samples. Different
f sputum (green), oropharynx (blue), and nasal (red) samples for
Table 3 Phyla that differ significantly between sample types
Phylum Mean relative abundance Sample comparison
TB patients Controls O vs N O vs S N vs S
Sputum Oropharynx Nasal Oropharynx Nasal All samples Controls TB patients TB patients TB patients
Bacteria
Bacteroidetes 11.015 11.16 0.30 30.72 1.02 0.00366 0.0095
Cyanobacteria 0 0.0016 0.064 0 0.22 0.00314
TM7 0.48 0.19 0.011 0.82 0.024 0.00799
Fusobacteria 4.30 2.49 0.10 12.84 0.26 0.0044
Thermi 0 0 0.081 0 0.062 0.00275 0.013 0.034
Actinobacteria 8.52 0.81 5.91 1.41 33.49 0.022 0.018 0.013
Unclassified Bacteria 0.25 0.21 0.064 0.48 0.043 0.011 0.0095 0.049
Spirochaetes 0.070 0.071 0 0.30 0 0.00549
SR1 0.0016 0.0079 0 0.18 0 0.00733
Gemmatimonadetes 0 0 0.016 0 0 0.00477
Chloroflexi 0 0 0.0048 0 0.036 0.0044
Acidobacteria 0 0 0.011 0 0 0.029
Tenericutes 0.0016 0.0079 0.0016 0.016 0 0.03
Fungi
Ascomycota 76.89 74.42 45.24 43.30 23.89 0.036 0.009
Unclassified Fungi 0.087 1.4 0.024 10.32 0 0.011 0.018
The relative abundance of the various phyla is shown on the left side. p values are shown on the right, only for phyla that were significantly different when
comparing between sample types from patients and controls together (all samples), or the control and TB patient groups separately. p values were corrected
using FDR. O oropharynx, N nasal, S sputum.
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in respiratory tract bacterial communities associated to
health status. The only difference between patient and
control groups, using either nasal and oropharynx samples
separately or both sample types (nasal and oropharynx)
together, was found in oropharynx samples, where unclas-
sified sequences belonging to the Streptococcaceae family
were more abundant in TB patients (p = 0.00878, not
shown). Taken together, these observations indicate alter-
ations in these communities and raise the possibility that
such imbalances could affect, or result from, infection
and/or colonization.
Fungal diversity
The fungal nuclear ribosomal internal transcribed spacer
ITS1 region was amplified using the primer set ITS-5
(5′GGAAGTAAAAGTCGTAACAAGG3′) and ITS-2 (5′
GCTGCGTTCTTCATCGATGC3′) [24] and conditions
as indicated above for Bacteria, but doing 35 cycles of 60 s
at 94°C, 60 s at 55.2°C, and 90 s at 72°C, followed by a
final extension for 10 min at 72°C. Amplicons were sub-
jected to pyrosequencing, and sequence analysis was done
as indicated above for Bacteria. Of a total of 783,925 raw
sequences obtained, 268,751 sequences with a length size
larger than 100 bps were retained after filtering for quality
(34.3%). Chimeras and non-rRNAs sequences werediscarded, as mentioned above for Bacteria, using 97% se-
quence identity set of fungal ITS sequences from the
UNITE database [25]. Samples were rarified to 2,076 reads
per sample (the number of reads per sample ranged from
1 to 42,479), leaving only 17 samples from patients (out of
18) and 7 from controls (out of 12). Nasal samples showed
greater fungal richness and diversity, although the dif-
ferences between patients and controls in samples of the
same type were not significant (Table 2). Overall, the ma-
jority of the ITS1 sequences analyzed (90%) were classified
as belonging to the phylum Ascomycota, followed by
Basidiomycota. This was observed for all sample types
with the exception of nasal samples from healthy control
individuals (Figure 2), and is consistent with nasal fungal
analysis in the nares [26]. However, the genus Malassezia
was not predominant in this study, as has been reported
previously for diverse skin sites, probably due to different
environmental conditions of the body sites sampled [26].
Again, communities clustered according to sample type
(oropharynx, nasal, and sputum) (Figure 2), and TB pa-
tient sputum and oropharynx samples showed similar
relative abundances with no significant differences at the
phylum level (Figure 2, Table 3). Significant differences
were observed only when comparing patient nasal com-
munities with those of the oropharynx (Ascomycota and
unclassified sequences) or sputum (unclassified sequences)
Figure 2 Phylum level analysis of fungal ITS1 sequences. The bottom shows classification for sequences obtained from TB patient (P) and
healthy control (C) sputum (S), oropharynx (O), and nasal (N) samples. The top indicates clustering analysis based on Jaccard distances.
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and controls were observed only in oropharynx samples,
with a decrease of the genus Cryptococcus in patients
(p = <1e−15, not shown). In TB patients, Candida and
Aspergillus were the most frequent genera for both spu-
tum and oropharyngeal samples, even though no signifi-
cant differences were found when compared with healthy
controls. In contrast to Bacteria, significant differences at
the phylum level between oropharynx and nasal sample
communities were seen only in patients with TB but not in
controls (Table 3). Previous work on skin microbial com-
munities indicated that bacterial and fungal richness did
not show a linear correlation and that diversity was
dependent on body site [26]. Similarly, in this study, the
diversity of bacterial and fungal communities was found to
vary inversely between samples analyzed: bacterial diversity
was greater in oropharynx when compared with nasal
samples, whereas fungi were more diverse in nasal than in
oropharynx samples (Table 2).
Conclusions
Differences in community diversity indexes and in
abundance of particular taxa, specifically in oropharynxcommunities, between TB patients and healthy controls
suggest disturbance of respiratory tract microbial commu-
nities, despite the overall similarity in terms of the major
phyla identified. These altered communities could either
result from or influence infection and/or colonization by
M. tuberculosis, a possibility that can be further examined
by studying changes in particular taxa or in functionality
via metagenomic sequencing using samples collected at
various time points. More importantly, there was a resem-
blance between communities from sputum in TB patients
and those present in the oropharynx, both of which were
distinct from the nasal microbiota. This study therefore
indicates that oropharynx samples can be valuable for
probing respiratory tract microbiota and sets the ground-
work for more extensive comparison and analysis of pos-
sible microbial community imbalances associated with a
diseased state such as TB.
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